EnteroBiotix partners with Imperial College London to advance microbiome therapeutics

Glasgow, Scotland – 10th November 2022. EnteroBiotix Limited (“EBX”), a premier, full-spectrum microbiome therapeutics company, today announced a partnership with Imperial College London (‘Imperial’) to develop microbiome R&D in patients suffering from blood cancer as well as accelerate systematic research in the new science of the microbiome.

Read full release.